Who Optimizes SG&A Costs Better? Zoetis Inc. or Alkermes plc

Optimizing SG&A Costs: A Tale of Two Companies

In the competitive landscape of the pharmaceutical industry, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Zoetis Inc. and Alkermes plc, two prominent players, have shown distinct strategies over the past decade. From 2014 to 2023, Zoetis Inc. consistently reported higher SG&A expenses, peaking at approximately $2.15 billion in 2023. This represents a 31% increase from their 2014 figures. In contrast, Alkermes plc's SG&A expenses grew by a staggering 245% over the same period, reaching around $690 million in 2023.

A Decade of Financial Strategy

While Zoetis Inc. maintains a larger scale of operations, their SG&A growth rate is more controlled compared to Alkermes plc. This suggests a more stable cost management approach. Investors and analysts should consider these trends when evaluating the financial health and strategic direction of these companies.